L-Dopa diglyceride L-Dopa – oral bioavailability low - Significant first pass effect - only 0.2 % via lymph L- Dopa diglyceride - 20 % via lymph The rationale for the prodrug is that the fatty acids in the l- and 3-positions are cleaved during lipid digestion leaving the 2-substituted L- Dopa derivative, as a 2 - monoglyceride mimic, which is absorbed and incorporated into the TG resynthesis pathway.
{}